Physician profile
Dennis R Scribner
NPI 1679545982
$76,238.99
in general payments reported to CMS, 2019-2025
37 companies · $5,110 in 2025
The $5,110 reported for 2025 was more than what 86% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $257 · 2021: $25K · 2022: $295 · 2023: $9,210 · 2024: $25K · 2025: $5,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $34K · Food and Beverage: $3,034 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $34,344.34 |
| Food and Beverage | $3,033.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $411.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $63,976.17 | 2019-2025 | Da Vinci Surgical System |
| Tesaro, INC. | $9,683.87 | 2019 | |
| Merck Sharp & Dohme LLC | $366.31 | 2019-2025 | Keytruda, Lynparza |
| Eisai INC. | $230.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $228.95 | 2019-2025 | |
| Genmab U.S., INC. | $204.54 | 2022-2025 | Tivdak |
| Glaxosmithkline, LLC. | $189.24 | 2020-2025 | Zejula, Jemperli |
| Davol INC. | $151.78 | 2025 | Arista, Channel Drain |
| Myriad Genetic Laboratories, INC. | $146.06 | 2020-2025 | Myrisk |
| Amgen INC. | $136.20 | 2019-2021 | |
| Seagen INC. | $129.41 | 2021-2024 | |
| Baxter Healthcare | $80.73 | 2019-2025 | Floseal, Perclot |
| Janssen Biotech, INC. | $74.06 | 2021-2022 | |
| Genzyme Corporation | $72.81 | 2019-2022 | |
| Astellas Pharma US INC | $52.16 | 2025 | Veozah |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $50.58 | 2024-2025 | Duraseal Exact Spinal Sealant System, Codman Hakim, Codman Certas |
| Lexicon Pharmaceuticals, INC. | $37.57 | 2019 | |
| Stryker Corporation | $33.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $33.18 | 2021-2024 | Spravato |
| Axonics, INC. | $30.89 | 2023 | Axonics |
| Molnlycke Health Care US, LLC | $29.21 | 2025 | Avance, Mepilex Border Post-Op Ag |
| Sumitomo Pharma America, INC. | $28.80 | 2025 | Myfembree |
| Immunogen, INC. | $24.51 | 2023 | Elahere |
| Abbvie INC. | $24.37 | 2025 | |
| Mylan Institutional INC. | $22.41 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.05 | 2021 | |
| Aspira Women'S Health INC | $21.15 | 2023 | Ova1 |
| Genentech USA, INC. | $20.49 | 2019 | |
| Exelixis INC. | $19.80 | 2019 | |
| Celgene Corporation | $17.55 | 2019 | |
| Aurobindo Pharma USA, INC. | $15.13 | 2019 | |
| Emd Serono, INC. | $15.08 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.80 | 2019 | |
| Kyowa Kirin, INC. | $14.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.18 | 2019 | |
| Foundation Medicine, INC. | $14.03 | 2019 | |
| Lilly USA, LLC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Scribner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.